Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Identification of SEC62 as a potential marker for 3q amplification and cellular migration in dysplastic cervical lesions

Authors: Maximilian Linxweiler, Florian Bochen, Bernhard Schick, Silke Wemmert, Basel Al Kadah, Markus Greiner, Andrea Hasenfus, Rainer-Maria Bohle, Ingolf Juhasz-Böss, Erich-Franz Solomayer, Zoltan Ferenc Takacs

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Chromosome 3 amplification affecting the 3q26 region is a common genomic alteration in cervical cancer, typically marking the transition of precancerous intraepithelial lesions to an invasive phenotype. Though potential 3q encoded target genes of this amplification have been identified, a functional correlation of potential oncogenic function is still missing. In this study, we investigated copy number changes and the expression level of SEC62 encoded at 3q26.2 as a new potential 3q oncogene in dysplastic cervical lesions and analyzed its role in cervical cancer cell biology.

Methods

Expression levels of Sec62 and vimentin were analyzed in liquid based cytology specimens from 107 women with varying grades of cervical dysplasia ranging from normal cases to cancer by immunofluorescence cytology. Additionally, a subset of 20 representative cases was used for FISH analyses targeting SEC62. To further explore the functional role of Sec62 in cervical cancer, HeLa cells were transfected with a SEC62 plasmid or SEC62 siRNA and analyzed for their proliferation and migration potential using real-time monitoring and trans-well systems as well as changes in the expression of EMT markers.

Results

FISH analyses of the swabbed cells showed a rising number of SEC62 gains and amplifications correlating to the grade of dysplasia with the highest incidence in high grade squamous intraepithelial lesions and squamous cell carcinomas. When analyzing the expression level of Sec62 and vimentin, we found a gradually increasing expression level of both proteins according to the severity of the dysplasia. In functional analyses, SEC62 silencing inhibited and SEC62 overexpression stimulated the migration of HeLa cells with only marginal effects on cell proliferation, the expression level of EMT markers and the cytoskeleton structure.

Conclusions

Our study suggests SEC62 as a target gene of 3q26 amplification and a stimulator of cellular migration in dysplastic cervical lesions. Hence, SEC62 could serve as a potential marker for 3q amplification, providing useful information about the dignity and biology of dysplastic cervical lesions.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Elit LM, Hirte H. Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert Rev Anticancer Ther. 2014;14:319–32.CrossRefPubMed
3.
Heselmeyer K, Macville M, Schrock E, Blegen H, Hellstrom AC, Shah K, et al. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Gene Chromosomes Cancer. 1997;19:233–40.CrossRef
4.
Allen DG, White DJ, Hutchins AM, Scurry JP, Tabrizi SN, Garland SM, et al. Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer. Br J Cancer. 2000;83:1659–63.CrossRefPubMedPubMedCentral
5.
Sugita M, Tanaka N, Davidson S, Sekiya S, Varella-Garcia M, West J, et al. Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung. Cancer Genet Cytogenet. 2000;117:9–18.CrossRefPubMed
6.
Caraway NP, Khanna A, Dawlett M, Guo M, Guo N, Lin E, et al. Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma. Gynecol Oncol. 2008;110:37–42.CrossRefPubMed
7.
Heselmeyer K, Schrock E, du Manoir S, Blegen H, Shah K, Steinbeck R, et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A. 1996;93:479–84.CrossRefPubMedPubMedCentral
8.
Huang FY, Kwok YK, Lau ET, Tang MH, Ng TY, Ngan HY. Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas. Cancer Genet Cytogenet. 2005;157:42–8.CrossRefPubMed
9.
Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, Lundsteen C, et al. Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer. 1999;24:144–50.CrossRefPubMed
10.
Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, Rienstein S, et al. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer. 2007;56:175–84.CrossRefPubMed
11.
Chang YC, Yeh KT, Liu TC, Chang JG. Molecular cytogenetic characterization of esophageal cancer detected by comparative genomic hybridization. J Clin Lab Anal. 2010;24:167–74.CrossRefPubMed
12.
Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC Med Genomics. 2009;2:21.CrossRefPubMedPubMedCentral
13.
Sheu JJ, Lee CH, Ko JY, Tsao GS, Wu CC, Fang CY, et al. Chromosome 3p12.3-p14.2 and 3q26.2-q26.32 are genomic markers for prognosis of advanced nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2009;18:2709–16.CrossRefPubMed
14.
Bockmühl U, Schwendel A, Dietel M, Petersen I. Distinct patterns of chromosomal alterations in high- and low-grade head and neck squamous cell carcinomas. Cancer Res. 1996;5:5325–9.
15.
Linxweiler M, Linxweiler J, Barth M, Benedix J, Jung V, Kim YJ, et al. Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer. Am J Pathol. 2012;180:473–83.CrossRefPubMed
16.
Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 2008;68:6913–21.CrossRefPubMedPubMedCentral
17.
McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med. 2010;182:83–91.CrossRefPubMedPubMedCentral
18.
Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003;63:7113–21.PubMed
19.
Comtesse N, Keller A, Diesinger I, Bauer C, Kayser K, Huwer H, et al. Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer. 2007;120:2538–44.CrossRefPubMed
20.
Jung SJ, Kim JE, Reithinger JH, Kim H. The Sec62-Sec63 translocon facilitates translocation of the C-terminus of membrane proteins. J Cell Sci. 2014;127:4270–8.CrossRefPubMed
21.
Reithinger JH, Kim JE, Kim H. Sec62 protein mediates membrane insertion and orientation of moderately hydrophobic signal anchor proteins in the endoplasmic reticulum (ER). J Biol Chem. 2013;288:18058–67.CrossRefPubMedPubMedCentral
22.
Lakkaraju AK, Thankappan R, Mary C, Garrison JL, Taunton J, Strub K. Efficient secretion of small proteins in mammalian cells relies on Sec62-dependent posttranslational translocation. Mol Biol Cell. 2012;23:2712–22.CrossRefPubMedPubMedCentral
23.
Greiner M, Kreutzer B, Jung V, Grobholz R, Hasenfus A, Stöhr RF, et al. Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer. 2011;128:2284–95.CrossRefPubMed
24.
Linxweiler M, Schorr S, Schauble N, Jung M, Linxweiler J, Langer F, et al. Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells. BMC Cancer. 2013;13:574.CrossRefPubMedPubMedCentral
25.
Linxweiler J, Kollipara L, Zahedi RP, Lampel P, Zimmermann R, Greiner M. Proteomic insights into non-small cell lung cancer: new ideas for cancer diagnosis and therapy from a functional viewpoint. EuPA Open Proteomics. 2014;4:25–39.CrossRef
26.
Lopez J, Poitevin A, Mendoza-Martinez V, Perez-Plasencia C, Garcia-Carranca A. Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer. 2012;12:48.CrossRefPubMedPubMedCentral
27.
Myong NH. Loss of E-cadherin and acquisition of vimentin in epithelial-mesenchymal transition are noble indicators of uterine cervix cancer progression. Korean J Pathol. 2012;46:341–8.CrossRefPubMedPubMedCentral
28.
Koay MH, Crook M, Stewart CJ. Cyclin D1, E-cadherin and beta-catenin expression in FIGO Stage IA cervical squamous carcinoma: diagnostic value and evidence for epithelial-mesenchymal transition. Histopathology. 2012;61:1125–33.CrossRefPubMed
29.
Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39:305–18.CrossRefPubMed
30.
Scanlon CS, Van Tubergen EA, Inglehart RC, D’Silva NJ. Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J Dent Res. 2013;92:114–21.CrossRefPubMed
31.
Lee MY, Chou CY, Tang MJ, Shen MR. Epithelial-Mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and Snail up-regulation. Clin Cancer Res. 2008;14:4743–50.CrossRefPubMed
32.
33.
Sabbah M, Amami S, Redeuilh G, Julein S, Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat. 2008;11:123–51.
34.
Wu TH, Chiou YW, Chiu WT, Tang MJ, Chen CH, Yeh ML. The F-actin and adherence-dependent mechanical differentiation of normal epithelial cells after TGF-ß1-induced EMT (tEMT) using a microplatemeasurement system. Biomed Microdevices. 2014;16:465–78.CrossRefPubMed
35.
Vessey CJ, Wilding J, Folarin N, Hirano S, Takeichi M, Soutter P, et al. Altered expression and function of E-cadherin in cervical intraepithelial neoplasia and invasive squamous cell carcinoma. J Pathol. 1995;176:151–9.CrossRefPubMed
36.
Reesink-Peters N, Wisman GB, Jéronimo C, Tokumaru CY, Cohen Y, Dong SM, et al. Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res. 2004;2:289–95.PubMed
37.
Xiaoxia H, Schwarz JK, Lewis Jr JS, Huettner PC, Rader JS, Deasy JO, et al. A MicroRNA expression signature for cervical cancer prognosis. Cancer Res. 2010;70:1441–8.CrossRef
38.
Duenas-Gonzalez A, Serrano-Olvera A, Cetina L, Coronel J. New molecular targets against cervical cancer. Int J Women’s Health. 2014;5:1023–31.CrossRef
39.
40.
Greiner M, Kreutzer B, Lang S, Jung V, Cavalié A, Unteregger G, et al. Sec62 protein level is crucial for the ER stress tolerance of prostate cancer. Prostate. 2011;71:1074–83.CrossRefPubMed
41.
42.
Kuglik P, Kasikova K, Smetana J, Vallova V, Lastuvkova A, Moukova L, et al. Molecular cytogenetic analyses of hTERC (3q26) and MYC (8q24) genes amplifications in correlation with oncogenic human papillomavirus infection in Czech patients with cervical intraepithelial neoplasia and cervical carcinomas. Neoplasma. 2015;62:130–9.CrossRefPubMed
43.
Wang X, Liu J, Xi H, Cai L. The significant diagnostic value of human telomerase RNA component (hTERC) gene detection in high-grade cervical lesions and invasive cancer. Tumour Biol. 2014;35:6893–900.CrossRefPubMed
44.
Kanao H, Enomoto T, Kimura T, Fujita M, Nakashima R, Ueda Y, et al. Overexpression of LAMP3/TSC403/DC-LAMP promotes metastasis in uterine cervical cancer. Cancer Res. 2005;65:8640–5.CrossRefPubMed
45.
Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, et al. PIK3CA as an oncogene in cervical cancer. Oncogene. 2000;19:2739–44.CrossRefPubMed
46.
Oyanagi J, Ogawa T, Sato H, Higashi S, Miyazaki K. Epithelial-mesenchymal transition stimulates human cancer cells to extend microtubule-based invasive protrusions and suppresses cell growth in collagen gel. PLoS One. 2012;7, e53209.CrossRefPubMedPubMedCentral
47.
Malicka-Blaszkiewicz M, Filipczak N, Golab K, Juszczynska K, Sebzda T, Gburek J. Ovocystatin affects actin cytoskeleton organization and induces proapoptotic acivity. Acta Biochim Pol. 2014;61:753–8.PubMed
48.
Carpenter Jr WT, Davis JM. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatry. 2012;17:1168–73.CrossRefPubMed
49.
Jalali GR, Herzog TJ, Dziura B, Walat R, Kilpatrick MW. Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding. Am J Obstet Gynecol. 2010;202:581.e1–5.CrossRef
Metadata
Title
Identification of SEC62 as a potential marker for 3q amplification and cellular migration in dysplastic cervical lesions
Authors
Maximilian Linxweiler
Florian Bochen
Bernhard Schick
Silke Wemmert
Basel Al Kadah
Markus Greiner
Andrea Hasenfus
Rainer-Maria Bohle
Ingolf Juhasz-Böss
Erich-Franz Solomayer
Zoltan Ferenc Takacs
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2739-6

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Review

Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia – can findings from animal models be translated to humans?

Research article

Highly sensitive detection of the PIK3CA H1047R mutation in colorectal cancer using a novel PCR-RFLP method

Research article

Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach

Research article

Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells

Case report

Complete response of extramedullary relapse in breast of acute T lymphoblastic leukemia after bone marrow transplantation to chemoradiotherapy: a case report and literature review

Research article

Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits